Best Places to Work
Filter News
Found 11,679 articles
-
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
4/3/2024
Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the first patient has been dosed in the REJOICE-Ovarian01 phase 2/3 trial evaluating the efficacy and safety of investigational raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer.
-
Alexion Canada Appoints Karen Heim as New General Manager
4/2/2024
Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is pleased to announce the appointment of Karen Heim as Vice President and General Manager, Canada, effective April 1st, 2024.
-
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
4/2/2024
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, announced that Gilead Sciences has elected to extend the research term of the companies’ ongoing collaboration, originally established in 2019, by an additional two years.
-
Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
4/2/2024
Bristol Myers Squibb published its 2023 Environmental, Social, and Governance Report detailing the company’s meaningful progress, evolved strategy, and aspirational goals toward its ESG efforts.
-
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
4/2/2024
AstraZeneca and Daiichi Sankyo’s Biologics License Application for datopotamab deruxtecan has been accepted in the US for the treatment of adult patients with unresectable or metastatic hormone receptor -positive, HER2-negative breast cancer who have received prior systemic therapy for unresectable or metastatic disease.
-
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
4/2/2024
Sutro Biopharma, Inc., a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates, announced the pricing of an underwritten offering of 14,478,764 shares of its common stock at a price of $5.18 per share.
-
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
4/2/2024
Daiichi Sankyo and AstraZeneca’s Biologics License Application for datopotamab deruxtecan has been accepted in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer who have received prior systemic therapy for unresectable or metastatic disease.
-
Merz Enters Asset Purchase Agreement With a US-Based Biotech Company
4/2/2024
Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered into an Asset Purchase Agreement to acquire two commercial medicines from NASDAQ-listed Acorda Therapeutics.
-
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
4/2/2024
Ipsen and Sutro Biopharma announced an exclusive global licensing agreement for STRO-003.
-
Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, April 24, 2024
4/2/2024
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2024 before the market opens on Wednesday, April 24, 2024, and will hold a conference call on the same day at 8:30 a.m. EDT.
-
Johnson & Johnson to Participate in the BofA Securities Health Care Conference
4/2/2024
Johnson & Johnson (NYSE: JNJ) will participate in the BofA Securities Health Care Conference on Tuesday, May 14th, at the Encore Hotel, Las Vegas, Nevada. John Reed, Executive Vice President, Innovative Medicine, R&D, will represent the Company in a session scheduled at 4:40 pm (Eastern Time).
-
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
4/1/2024
2seventy bio, Inc., announced the completion of the asset purchase agreement by Regeneron Pharmaceuticals, Inc. Under the terms of the APA, Regeneron has acquired all oncology and autoimmune research and development programs and has hired approximately 160 employees from 2seventy bio as part of their newly launched cell medicines business.
-
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or...
4/1/2024
Zai Lab Limited partner Bristol Myers Squibb announced the pivotal Phase 3 KRYSTAL-12 study, evaluating KRAZATI® as a monotherapy in patients with pretreated locally advanced or metastatic non-small cell lung cancer harboring a KRASG12C mutation, met the primary endpoint of progression-free survival and the key secondary endpoint of overall response rate as assessed by Blinded Independent Central Review at final analysis for these endpoints.
-
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 01, 2024
4/1/2024
Poseida Therapeutics, Inc. announced that the Compensation Committee of its Board of Directors granted an inducement award to Syed Rizvi, M.D., the Company's new Chief Medical Officer.
-
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
4/1/2024
Merck, known as MSD outside of the United States and Canada, will hold its first-quarter 2024 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, April 25.
-
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
4/1/2024
Acorda Therapeutics, Inc. announced that it has entered into an asset purchase agreement with Merz Therapeutics to purchase substantially all of the assets of Acorda, including the rights to INBRIJA, AMPYRA, and FAMPYRA for $185 million.
-
Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
4/1/2024
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced its New Drug Submission (NDS) for exagamglogene autotemcel (exa-cel) has been accepted for Priority Review by Health Canada.
-
The Kinetix Group and Pfizer Health Equity Work Recognized by PM360
3/29/2024
The Kinetix Group and Pfizer Inflammation and Immunology received a PM360 Pharma Choice Award for their recent health equity initiative.
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 29, 2024
3/29/2024
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on March 29, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired by Sarepta in March 2024.
-
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
3/28/2024
Bristol Myers Squibb (NYSE: BMY) today announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE clinical trial program evaluating Zeposia (ozanimod) in adult patients with moderate to severe active Crohn’s disease.